Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

BACKGROUND: This study was initiated to investigate the difference in HER2 status between tumor tissue and circulating tumor cells (CTCs), as well as the predictive value of CTC HER2 status for predicting the outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer (MBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shaohua, Li, Lei, Wang, Tao, Bian, Li, Hu, Haixu, Xu, Chunhong, Liu, Bing, Liu, Yi, Cristofanilli, Massimo, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960713/
https://www.ncbi.nlm.nih.gov/pubmed/27456503
http://dx.doi.org/10.1186/s12885-016-2578-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960713/
https://www.ncbi.nlm.nih.gov/pubmed/27456503
http://dx.doi.org/10.1186/s12885-016-2578-5

Ejemplares similares